Table 2 Baseline characteristics of the entire patient cohort
No. (%) | P | |||
|---|---|---|---|---|
the entire cohort (n = 4262) | MRM ± RT (n = 3858) | BCS + RT (n = 404) | ||
Year | < .001 | |||
1999–2008 | 1976 (46.4) | 1871 (48.5) | 105 (26.0) | |
2009–2014 | 2286 (53.6) | 1987 (51.5) | 299 (74.0) | |
Age (years) | < .001 | |||
≤ 40 | 802 (18.8) | 678 (17.6) | 124 (30.7) | |
> 40 | 3460 (81.2) | 3180 (82.4) | 280 (69.3) | |
Tumor location | .755 | |||
Inner quadrant | 909 (21.3) | 819 (21.2) | 90 (22.3) | |
Other quadrants | 3292 (77.2) | 2985 (77.4) | 307 (76.0) | |
Unknown | 61 (1.4) | 54 (1.4) | 7 (1·.7) | |
T stage | < .001 | |||
T1 | 2009 (47.1) | 1725 (44.7) | 284 (70.3) | |
T2 | 2253 (52.9) | 2133 (55.3) | 120 (29.7) | |
SLNB | < .001 | |||
No | 4099 (96.2) | 3782 (98.0) | 317 (78.5) | |
Yes | 163 (3.8) | 76 (2.0) | 87 (21.5) | |
No. of ALND | .834 | |||
≤ 19 | 2721 (63.8) | 2465 (63.9) | 256 (63.4) | |
> 19 | 1541 (36.2) | 1393 (36.1) | 148 (36.6) | |
No. of positive nodes | .016 | |||
1 | 2198 (51.6) | 1963 (50.9) | 235 (58.2) | |
2 | 1264 (29.7) | 1156 (30.0) | 108 (26.7) | |
3 | 800 (18.8) | 739 (19.2) | 61 (15.1) | |
Lymphovascular invasion | < .001 | |||
No | 3457 (81.1) | 3109 (80.6) | 348 (86.1) | |
Yes | 522 (12.2) | 470 (12.2) | 52 (12.9) | |
unknown | 283 (6.6) | 279 (7.2) | 4 (1.0) | |
Histological grade | < .001 | |||
I | 133 (3.1) | 104 (2.7) | 29 (7.2) | |
II | 2290 (53.7) | 2035 (52.7) | 255 (63.1) | |
III | 1030 (24.2) | 937 (24.3) | 93 (23.0) | |
unknown | 809 (19.0) | 782 (20.3) | 27 (6.7) | |
Chemotherapy | < .001 | |||
No | 239 (5.6) | 236 (6.1) | 3 (0.7) | |
Yes | 3995 (93.7) | 3594 (93.2) | 401 (99.3) | |
unknown | 28 (0.7) | 28 (0.7) | 0 (0) | |
Chemotherapeutic drug | < .001 | |||
Taxane-based | 2684 (63.0) | 2344 (60.8) | 340 (84.2) | |
Others | 1105 (25.9) | 1057 (27.4) | 48 (11.9) | |
Unknown | 473 (11.1) | 457 (11.8) | 16 (4.0) | |
Hormone receptor & Hormonal therapy | < .001 | |||
negative & no | 913 (21.4) | 862 (22.3) | 51 (12.6) | |
positive & yes | 2862 (67.2) | 2537 (65.8) | 325 (80.4) | |
positive & no | 312 (7.3) | 295 (7.6) | 17 (4.2) | |
Unknown | 175 (4.1) | 164 (4.3) | 11 (2.7) | |
HER2 & Target therapy | < .001 | |||
negative & no | 2846 (66.8) | 2545 (66.0) | 301 (74.5) | |
positive & yes | 233 (5.5) | 198 (5.1) | 35 (8.7) | |
positive & no | 619 (14.5) | 582 (15.1) | 37 (9.2) | |
unknown | 564 (13.2) | 533 (13.8) | 31 (7.7) | |